Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Stock Price Down 2.8% – What’s Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF)’s share price fell 2.8% on Tuesday . The stock traded as low as $28.94 and last traded at $28.97. 500 shares changed hands during mid-day trading, an increase of 1,645% from the average session volume of 29 shares. The stock had previously closed at $29.79.

Swedish Orphan Biovitrum Stock Performance

The firm’s 50-day moving average price is $29.83 and its two-hundred day moving average price is $29.53. The firm has a market capitalization of $10.31 billion, a PE ratio of 24.34 and a beta of 0.46. The company has a quick ratio of 0.66, a current ratio of 1.00 and a debt-to-equity ratio of 0.22.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its earnings results on Wednesday, July 16th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.06. The business had revenue of $649.61 million for the quarter, compared to the consensus estimate of $644.68 million. Swedish Orphan Biovitrum had a net margin of 16.05% and a return on equity of 11.67%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.